Jennifer Nwankwo Ph.D. is the founder and CEO @ 1910 Genetics. 1910 Genetics is a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Their mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.
They have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization.
They are currently applying their technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.
They are fortunate to have closed Series A and Seed funding from awesome investors including M12 - Microsoft's Venture Fund, Playground Global, Sam Altman's Apollo Projects, Y Combinator, FoundersX Ventures, Scientia Ventures, and many others.
Jen has a Ph.D.in Pharmacology & Experimental Therapeutics from Tufts University School of Medicine as well as a Doctoral Research in Hematology & Platelet Biology from Harvard Medical School.
Sources: Crunchbase, LinkedIn, YCombinator,
Comments